The Research-Based Pharmaceutical Industry

Resistant against Business Cycle Fluctuations

Long-term development of production

The pharmaceutical industry in general and the group of research-based pharmaceutical companies in particular are less business cycle-dependent than other German industries. Comparing production, export turnover and employment data in the chemical, manufacturing and research-based pharmaceutical industry, the latter seems to be basically resistant to cyclical fluctuations. However, in the present economic downturn employment in the pharmaceutical industry shows a stark decline which can be explained with special effects. The results of the analysis as well as the underlying data must be handled with care, however. On the one hand, official statistics do not always provide consistent long-term time series. On the other hand, data collected by the German Association of Research-based Pharmaceutical Companies (vfa) do not always correspond with the classification used by the Federal Statistical Office.

More articles on the topic

1 2
 
IW-Newsletter
No. 5 from December 23, 2011
The US Health System and Recent Health Care Reform: Centennial Reform or Nonstarter?
In March 2010 the American Congress passed a health care reform which requires every American citizen to buy a health insurance.
more
IW-Newsletter
No. 5 from December 23, 2011
The link between orders and production in manufacturing: Harder to Predict in Boom Time
During the economic boom from 2005 to 2008 Germany’s manufacturing industry saw an uncoupling of incoming orders and production that was unobserved during as well as after the recession.
more
IW-Newsletter
No. 4 from November 23, 2011
IW Forecast for Germany Autumn 2011: No Recession But Imponderabilities
Germany’s growth will slow markedly. In spite of the resurgence of finan­cial market problems, a recession seems, nevertheless, improbable.
more
IW-Newsletter
No. 3 from July 27, 2011
Rising raw material prices: German Businesses Struggle To Stay Afloat
According to an IW survey, German companies regard rising and volatile prices of raw materials as an essential resource risk for their business.
more
IW-Newsletter
No. 6 from December 1, 2010
Reforming Germany’s statutory health insurance: From Contribution Rate to Flat Premium
In 2010, the government subsidizes the German statutory health insurance with 15.7 billion euro thereby lowering the contribution rate for the insured by 1.6 percentage points to 14.9 percent regardless of their household income.
more
1 2
IW-Newsletter - No. 4 from July 8, 2010
[ImagePath_HyperLink1]

Quarterly English Summaries of IW Studies.

Further articles of this issue

Taxes on Utility Verhicles in Europe

German UV Owners and Drivers Pay Dearly

German Exports to Emerging Markets

One-fourth of Total Exports

Wage Policies between 2000 and 2009

An Informal Pact to Secure Employment

Flexible Employment in Germany

Stepping Stone and Risk

Newsletter: Newsletter (in Englisch)